A Population Pharmacokinetic Model of Tocilizumab in Kidney Transplant Patients Treated for Chronic Active Antibody-Mediated Rejection: Comparison of Plasma Exposure Between Intravenous and Subcutaneous Administration Schemes.
Capucine ArrivéCaroline BazzoliThomas JouveJohan NobleLionel RostaingFrançoise Stanke-LabesqueZoubir DjeradaPublished in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2024)
From month 3 of treatment, the subcutaneous and intravenous tocilizumab administration schemes provided average bioequivalent pharmacokinetic exposure at the population level but not at the individual level. Body weight, inflammation, ACR, and administration scheme should be considered to personalize the dose of tocilizumab for patients with CAAMR. Further studies are required to determine the target of tocilizumab exposure in kidney transplant patients with CAAMR.